Citadel Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Citadel Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,300	Closed	-$6.33K	–	15447
2023 Q2	$6.33K	Sell	11,300 -18,700	-62%	-$16.5K	﹤0.01%	13432
2023 Q1	$34.2K	Sell	30,000 -11,600	-28%	-$13.9K	﹤0.01%	12603
2022 Q4	$46.6K	Buy	41,600 +1,900	+5%	+$3.03K	﹤0.01%	12223
2022 Q3	$83K	Buy	39,700 +26,600	+203%	+$51.7K	﹤0.01%	11252
2022 Q2	$18K	Sell	13,100 -1,800	-12%	-$2.61K	﹤0.01%	12447
2022 Q1	$25K	Buy	+14,900	New	+$21.3K	﹤0.01%	13182

Other funds holding RVLP

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

TAM

Titleist Asset Management San Antonio, Texas $1.49B AUM 22.27% 1-Year Est. Return

Citadel Advisors's RVLP Position: Q3 2023 in Review

Citadel Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2023, closing a stake of 51,693 shares — an estimated $29K sold.

Citadel Advisors first reported a position in RVLP in Q2 2019 and held it in 8 quarters. The position peaked at $190K in Q1 2020. 32 funds tracked by Wall St. Rank hold RVLP as of Q3 2023.

Citadel Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 51,693 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2023, an estimated $29K.
Citadel Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2019 and held it in 8 quarters.
Citadel Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $190K in Q1 2020.
32 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.